Quan Dong Nguyen, MD, on Sirolimus's Potential to Change Uveitis Treatment
MAY 10, 2017
Findings from the trials have been favorable, and the drug is currently under FDA review. Nguyen says the limited number of uveitis specialists in the United States and worldwide creates a demand for better treatments with easier delivery methods.
“To me this would be quite revolutionary, should we be able to have this modality and this mode of treatment for the patient, because it’s delivered locally,” he said, also citing the safety advantages of the drug over corticosteroids. “Hopefully, if we have an immunomodulating agent that is able to control the inflammation, such as intravitreal sirolimus, and at the same time not have the side effects associated with corticosteroid, that would be very welcome.”